TOVX - PRICE - Theriva Biologics, Inc.

The development of the biotechnology business of Theriva Biologics, Inc. (TOVX) is not subject to the influence of economic cycles or seasonality, demonstrating high macro-resilience. The company's success relies on the effectiveness of viral methods for combating tumors, patent purity, and patient survival rates. The current indicator is 0.22. Amidst fierce competition for market share, the company seeks to commercialize its developments. This chart illustrates the price action of this immunotherapy developer.

To minimize fundamental risks, investors select assets with stable capitalization where the price serves as a market equivalent of the business's current value relative to its competitors. Since Theriva Biologics, Inc. (TOVX) generates no revenue and relies on external financing, this price chart reflects a speculative assessment of immuno-oncology platform prospects rather than operating profit, demonstrating the stock's sensitivity to grant news.